Apricitabine

Generic Name
Apricitabine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H11N3O3S
CAS Number
160707-69-7
Unique Ingredient Identifier
K1YX059ML1
Background

Apricitabine has been used in trials studying the treatment of HIV Infections.

Associated Conditions
-
Associated Therapies
-

A Long Term Safety Study of Apricitabine in HIV-infected Patients

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2008-05-29
Last Posted Date
2011-06-23
Lead Sponsor
Avexa
Registration Number
NCT00686270

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-02-12
Last Posted Date
2012-01-23
Lead Sponsor
Avexa
Target Recruit Count
239
Registration Number
NCT00612898
Locations
🇺🇸

Summa Health System, Akron, Ohio, United States

🇺🇸

Nicholaos C Bellos, MD, PA, Dallas, Texas, United States

🇺🇸

University of Texas Medical Brach, Galveston, Texas, United States

and more 97 locations

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-08-24
Last Posted Date
2011-06-23
Lead Sponsor
Avexa
Target Recruit Count
42
Registration Number
NCT00367952
Locations
🇦🇺

Avexa (co-ordinating sites in Australia and Argentina), Melbourne, Victoria, Australia

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

Phase 1
Completed
Conditions
First Posted Date
2006-07-14
Last Posted Date
2011-06-23
Lead Sponsor
Avexa
Target Recruit Count
18
Registration Number
NCT00352066
Locations
🇺🇸

Jasper Clinic Inc, Kalamazoo, Michigan, United States

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

Phase 1
Completed
Conditions
First Posted Date
2006-06-08
Last Posted Date
2011-06-23
Lead Sponsor
Avexa
Target Recruit Count
37
Registration Number
NCT00334659
Locations
🇺🇸

Jasper Clinic Inc., Kalamazoo, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath